Merck Sharp & Dohme’s Victory Over Claims Against Januvia and Janumet

Williams & Connolly LLP advised Merck Sharp & Dohme on the deal.

Merck Sharp & Dohme obtained twin summary judgment victories, resulting in the dismissal of claims by more than 2,000 plaintiffs related to Merck’s popular diabetes treatments, Januvia and Janumet.  

The team crafted and led a comprehensive, decade-long litigation strategy designed to focus attention on two dispositive issues—first, that the FDA’s repeated confirmation of these products’ safety profile preempts plaintiffs’ state-law claims (impossibility preemption); and second, available scientific evidence robustly supports the current labeling of the product (general causation).    

Judge Anthony J. Battaglia, of the United States District Court for the Southern District of California, granted both motions for summary judgment, resulting in dismissal with prejudice of plaintiffs’ claims.  

The Williams & Connolly team representing Merck in this matter includes Paul Boehm (Picture), Ana Reyes, Doug Marvin, Steve Raber, Kait Beach, Shayon Ghosh, Emily Pistilli, and Jessica Pinkham.   


Involved fees earner: Kaitlin Beach – Williams & Connolly LLP; Paul Boehm – Williams & Connolly LLP; Shayon Ghosh – Williams & Connolly LLP; Douglas Marvin – Williams & Connolly LLP; Stephen Raber – Williams & Connolly LLP; Emily Renshaw Pistilli – Williams & Connolly LLP; Ana Reyes – Williams & Connolly LLP;

Law Firms: Williams & Connolly LLP;

Clients: Merck Sharp & Dohme Corp.;

Author: Martina Bellini